How metabolism generates signals during innate immunity and inflammation

Journal of Biological Chemistry

Volumn 288, Issue 32, 2013, Pages 22893-22898

  McGettrick, Anne F ^a   O'Neill, Luke A J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL CRYSTALS; HYPOXIA-INDUCIBLE FACTOR 1; METABOLIC CHANGES; METABOLIC DISORDERS; NOD-LIKE RECEPTORS; PROINFLAMMATORY CYTOKINES; TOLL-LIKE RECEPTORS; TYPE-2 DIABETES;

ENZYME ACTIVITY; IMMUNE SYSTEM; METABOLITES; PATHOLOGY; PHYSIOLOGY;

METABOLISM;

ADENYLATE KINASE; CHOLESTEROL; CRYOPYRIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MALATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PATTERN RECOGNITION RECEPTOR; SIRTUIN 1; SIRTUIN 2; TOLL LIKE RECEPTOR 4; URIC ACID;

ATHEROSCLEROSIS; BIOGENESIS; CITRIC ACID CYCLE; CONFORMATIONAL TRANSITION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; FATTY ACID OXIDATION; GLYCOLYSIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; METABOLIC REGULATION; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

INFLAMMATION; INNATE IMMUNITY; METABOLIC DISEASES; METABOLIC REGULATION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1BETA; SIRTUIN 1; SIRTUIN 2; TOLL-LIKE RECEPTORS;

EID: 84881460276     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R113.486464     Document Type: Review

References (53)

1. McGettrick, A. F., and O'Neill, L. A. (2004) The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol. Immunol. 41, 577-582
2. Bryant, C., and Fitzgerald, K. A. (2009) Molecular mechanisms involved in inflammasome activation. Trends Cell Biol. 19, 455-464
3. Connolly, D. J., and O'Neill, L. A. (2012) New developments in Toll-like receptor targeted therapeutics. Curr. Opin. Pharmacol. 12, 510-518
4. Hennessy, E. J., Parker, A. E., and O'Neill, L. A. (2010) Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307
5. Wen, H., Ting, J. P., and O'Neill, L. A. (2012) A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat. Immunol. 13, 352-357
6. Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., Zheng, L., Gardet, A., Tong, Z., Jany, S. S., Corr, S. C., Haneklaus, M., Caffrey, B. E., Pierce, K., Walmsley, S., Beasley, F. C., Cummins, E., Nizet, V., Whyte, M., Taylor, C. T., Lin, H., Masters, S. L., Gottlieb, E., Kelly, V. P., Clish, C., Auron, P. E., Xavier, R. J., and O'Neill, L. A. (2013) Succinate is an inflammatory signal that induces IL-1 through HIF-1. Nature 496, 238-242
7. Misawa, T., Takahama, M., Kozaki, T., Lee, H., Zou, J., Saitoh, T., and Akira, S. (2013) Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 14, 454-460
8. Newsholme, P., Curi, R., Gordon, S., and Newsholme, E. A. (1986) Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. Biochem. J. 239, 121-125
9. Warburg, O., Wind, F., and Negelein, E. (1927) The metabolism of tumors in the body. J. Gen. Physiol. 8, 519-530
10. Warburg, O., Gawehn, K., and Geissler, A. W. (1958) Metabolism of leukocytes. Z. Naturforsch. B 13B, 515-516
11. Krawczyk, C. M., Holowka, T., Sun, J., Blagih, J., Amiel, E., DeBerardinis, R. J., Cross, J. R., Jung, E., Thompson, C. B., Jones, R. G., and Pearce, E. J. (2010) Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115, 4742-4749
12. Vazquez, A., Liu, J., Zhou, Y., and Oltvai, Z. N. (2010) Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst. Biol. 4, 58
13. Garedew, A., Henderson, S. O., and Moncada, S. (2010) Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ. 17, 1540-1550
14. Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., and Chi, H. (2011) HIF1-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367-1376
15. Chang, C. H., Curtis, J. D., Maggi, L. B., Jr., Faubert, B., Villarino, A. V., O'Sullivan, D., Huang, S. C., van der Windt, G. J., Blagih, J., Qiu, J., Weber, J. D., Pearce, E. J., Jones, R. G., and Pearce, E. L. (2013) Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239-1251
16. van der Windt, G. J., Everts, B., Chang, C. H., Curtis, J. D., Freitas, T. C., Amiel, E., Pearce, E. J., and Pearce, E. L. (2012) Mitochondrial respiratory capacity is a critical regulator of CD8 T cell memory development. Immunity 36, 68-78
17. O'Neill, L. A., and Hardie, D. G. (2013) Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493, 346-355
18. Icard, P., Poulain, L., and Lincet, H. (2012) Understanding the central role of citrate in the metabolism of cancer cells. Biochim. Biophys. Acta 1825, 111-116
19. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241
20. Joosten, L. A., Netea, M. G., Mylona, E., Koenders, M. I., Malireddi, R. K., Oosting, M., Stienstra, R., van de Veerdonk, F. L., Stalenhoef, A. F., Giamarellos-Bourboulis, E. J., Kanneganti, T. D., and van der Meer, J. W. (2010) Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1 production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248
21. McGonagle, D., Tan, A. L., Shankaranarayana, S., Madden, J., Emery, P., and McDermott, M. F. (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 66, 1683-1684
22. Schlesinger, N., De Meulemeester, M., Pikhlak, A., Yücel, A. E., Richard, D., Murphy, V., Arulmani, U., Sallstig, P., and So, A. (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res. Ther. 13, R53
23. Ridker, P. M., Thuren, T., Zalewski, A., and Libby, P. (2011) Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597-605
24. Hansson, G. K. (2005) Inflammation, atherosclerosis, and coronary artery disease. New Engl. J. Med. 352, 1685-1695
25. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., Espevik, T., Lien, E., Fitzgerald, K. A., Rock, K. L., Moore, K. J., Wright, S. D., Hornung, V., and Latz, E. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361
26. Tannahill, G. M., and O'Neill, L. A. (2011) The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3. FEBS Lett. 585, 1568-1572
27. Galea, J., Armstrong, J., Gadsdon, P., Holden, H., Francis, S. E., and Holt, C. M. (1996) Interleukin-1 in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16, 1000-1006
28. Moyer, C. F., Sajuthi, D., Tulli, H., and Williams, J. K. (1991) Synthesis of IL-1 and IL-1 by arterial cells in atherosclerosis. Am. J. Pathol. 138, 951-960
29. Olofsson, P. S., Sheikine, Y., Jatta, K., Ghaderi, M., SamnegArd, A., Eriksson, P., and Sirsjö, A. (2009) A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1:interleukin-1 receptor antagonist balance in atherosclerosis. Circ. J. 73, 1531-1536
30. Violi, F., Basili, S., Nigro, C., and Pignatelli, P. (2009) Role of NADPH oxidase in atherosclerosis. Future Cardiol. 5, 83-92
31. Liu, T. F., Vachharajani, V. T., Yoza, B. K., and McCall, C. E. (2012)NAD-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol. Chem. 287, 25758-25769
32. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M. W., and Guarente, L. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-. Nature 429, 771-776
33. Lin, J., Handschin, C., and Spiegelman, B. M. (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361-370
34. Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., and Mayo, M. W. (2004) Modulation of NF-B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23, 2369-2380
35. Yoshizaki, T., Milne, J. C., Imamura, T., Schenk, S., Sonoda, N., Babendure, J. L., Lu, J. C., Smith, J. J., Jirousek, M. R., and Olefsky, J. M. (2009) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 29, 1363-1374
36. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., and Dixit, V. D. (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188
37. Liu, T. F., Yoza, B. K., El Gazzar, M., Vachharajani, V. T., and McCall, C. E. (2011) NAD-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J. Biol. Chem. 286, 9856-9864
38. Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., and Thompson, C. B. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293
39. Hawley, S. A., Fullerton, M. D., Ross, F. A., Schertzer, J. D., Chevtzoff, C., Walker, K. J., Peggie, M. W., Zibrova, D., Green, K. A., Mustard, K. J., Kemp, B. E., Sakamoto, K., Steinberg, G. R., and Hardie, D. G. (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918-922
40. Beckers, A., Organe, S., Timmermans, L., Vanderhoydonc, F., Deboel, L., Derua, R., Waelkens, E., Brusselmans, K., Verhoeven, G., and Swinnen, J. V. (2006) Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol. Cancer Ther. 5, 2211-2217
41. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z. W., Karin, M., and Shoelson, S. E. (2001) Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKB. Science 293, 1673-1677
42. Goldfine, A. B., Fonseca, V., Jablonski, K. A., Pyle, L., Staten, M. A., Shoelson, S. E., and TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346-357
43. Pilon, G., Dallaire, P., and Marette, A. (2004) Inhibition of inducible nitricoxide synthase by activators of AMP-activated protein kinase. A new mechanism of action of insulin-sensitizing drugs. J. Biol. Chem. 279, 20767-20774
44. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174
45. Yang, Z., Kahn, B. B., Shi, H., and Xue, B. Z. (2010) Macrophage 1 AMPactivated protein kinase (1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 285, 19051-19059
46. MacIver, N. J., Blagih, J., Saucillo, D. C., Tonelli, L., Griss, T., Rathmell, J. C., and Jones, R. G. (2011) The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J. Immunol. 187, 4187-4198
47. Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C. L., Vera, D. R., and Shaw, R. J. (2009) mTOR and HIF-1-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. U.S.A. 106, 11137-11142
48. Lan, F., Cacicedo, J. M., Ruderman, N., and Ido, Y. (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 283, 27628-27635
49. Price, N. L., Gomes, A. P., Ling, A. J., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., Hubbard, B. P., Varela, A. T., Davis, J. G., Varamini, B., Hafner, A., Moaddel, R., Rolo, A. P., Coppari, R., Palmeira, C. M., de Cabo, R., Baur, J. A., and Sinclair, D. A. (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15, 675-690
50. Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., and Auwerx, J. (2009) AMPK regulates energy expenditure by modulatingNAD metabolism and SIRT1 activity. Nature 458, 1056-1060
51. Dhahbi, J. M., Mote, P. L., Wingo, J., Tillman, J. B., Walford, R. L., and Spindler, S. R. (1999) Calories and aging alter gene expression for gluconeogenic, glycolytic, and nitrogen-metabolizing enzymes. Am. J. Physiol. 277, E352-E360
52. Loenarz, C., and Schofield, C. J. (2011) Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem. Sci. 36, 7-18
53. Donohoe, D. R., Collins, L. B., Wali, A., Bigler, R., Sun, W., and Bultman, S. J. (2012) The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol. Cell 48, 612-626